Poststatin | CAS#135219-43-1 | prolyl endopeptidase inhibitor

MedKoo Cat#: 598107 | Name: Poststatin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Poststatin is an inhibitor of prolyl endopeptidase; produced by Streptomyces viridochromogenes MH534-30F3.

Chemical Structure

Poststatin

CAS#135219-43-1

Theoretical Analysis

MedKoo Cat#: 598107

Name: Poststatin

CAS#: 135219-43-1

Chemical Formula: C26H47N5O7

Exact Mass: 541.3475

Molecular Weight: 541.69

Elemental Analysis: C, 57.65; H, 8.75; N, 12.93; O, 20.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Poststatin; Postostatin;

IUPAC/Chemical Name

((S)-3-((S)-2-((S)-2-amino-3-methylbutanamido)-3-methylbutanamido)-2-oxopentanoyl)-D-leucyl-L-valine

InChi Key

LRXVQHCIMZSTJH-WPVAHCMFSA-N

InChi Code

InChI=1S/C26H47N5O7/c1-10-16(28-24(35)19(14(6)7)30-23(34)18(27)13(4)5)21(32)25(36)29-17(11-12(2)3)22(33)31-20(15(8)9)26(37)38/h12-20H,10-11,27H2,1-9H3,(H,28,35)(H,29,36)(H,30,34)(H,31,33)(H,37,38)/t16-,17+,18-,19-,20-/m0/s1

SMILES Code

OC([C@H](C(C)C)NC([C@@H](CC(C)C)NC(C([C@H](CC)NC([C@H](C(C)C)NC([C@H](C(C)C)N)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 541.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tsuda M, Muraoka Y, Someno T, Nagai M, Aoyagi T, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase. VI. Endopeptidase inhibitory activity of poststatin analogues containing pyrrolidine ring. J Antibiot (Tokyo). 1996 Sep;49(9):900-8. PubMed PMID: 8931724. 2: Tsuda M, Muraoka Y, Nagai M, Takeuchi T, Aoyagi T. Poststatin, a new inhibitor of prolyl endopeptidase. IV. The chemical synthesis of poststain. J Antibiot (Tokyo). 1996 Mar;49(3):287-91. PubMed PMID: 8626246. 3: Tsuda M, Muraoka Y, Nagai M, Aoyagi T, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase. VII. N-cycloalkylamide analogues. J Antibiot (Tokyo). 1996 Sep;49(9):909-20. PubMed PMID: 8931725. 4: Katori M, Majima M. Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension. Prog Drug Res. 2014;69:59-109. Review. PubMed PMID: 25130040. 5: Nagai M, Ogawa K, Muraoka Y, Naganawa H, Aoyagi T, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase, produced by Streptomyces viridochromogenes MH534-30F3. II. Structure determination and inhibitory activities. J Antibiot (Tokyo). 1991 Sep;44(9):956-61. PubMed PMID: 1938618. 6: Tsuda M, Muraoka Y, Nagai M, Aoyagi T, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase. III. Optical resolution of 3-amino-2-hydroxyvaleric acid and absolute configuration of poststatin. J Antibiot (Tokyo). 1996 Mar;49(3):281-6. PubMed PMID: 8626245. 7: Tsuda M, Muraoka Y, Nagai M, Aoyagi T, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase. VIII. Endopeptidase inhibitory activity of non-peptidyl poststatin analogues. J Antibiot (Tokyo). 1996 Oct;49(10):1022-30. PubMed PMID: 8968396. 8: Aoyagi T, Nagai M, Ogawa K, Kojima F, Okada M, Ikeda T, Hamada M, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase, produced by Streptomyces viridochromogenes MH534-30F3. I. Taxonomy, production, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo). 1991 Sep;44(9):949-55. PubMed PMID: 1938617. 9: Majima M, Shima C, Saito M, Kuribayashi Y, Katori M, Aoyagi T. Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine. Eur J Pharmacol. 1993 Mar 2;232(2-3):181-90. PubMed PMID: 8467857. 10: Tsuda M, Muraoka Y, Nagai M, Aoyagi T, Takeuchi T. Poststatin, a new inhibitor of prolyl endopeptidase. V. Endopeptidase inhibitory activity of poststatin analogues. J Antibiot (Tokyo). 1996 Sep;49(9):890-9. PubMed PMID: 8931723. 11: Dietsch AM, Clark HM, Steiner JN, Solomon NP. Effects of Age, Sex, and Body Position on Orofacial Muscle Tone in Healthy Adults. J Speech Lang Hear Res. 2015 Aug 1;58(4):1145-50. doi: 10.1044/2015_JSLHR-S-14-0325. PubMed PMID: 25951413. 12: Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S47-57. doi: 10.1016/j.jacl.2014.02.011. PubMed PMID: 24793441. 13: Kiderman A, Ben-Dov IZ, Glikberg F, Ackerman Z. Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem. Eur J Gastroenterol Hepatol. 2008 Oct;20(10):1002-5. doi: 10.1097/MEG.0b013e3282fdf64c. PubMed PMID: 18787468. 14: Mancini GB. Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statin Era of Lipid Management. Can J Cardiol. 2016 Mar;32(3):271-4. doi: 10.1016/j.cjca.2015.07.006. Epub 2015 Jul 11. Review. PubMed PMID: 26577895. 15: Ohshiro T, Ohtawa M, Nagamitsu T, Matsuda D, Yagyu H, Davis MA, Rudel LL, Ishibashi S, Tomoda H. New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models. J Pharmacol Exp Ther. 2015 Nov;355(2):299-307. doi: 10.1124/jpet.115.227348. Epub 2015 Sep 3. PubMed PMID: 26338984; PubMed Central PMCID: PMC4613958. 16: Katori M, Majima M. A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept. Pharmaceuticals (Basel). 2010 Jan 7;3(1):59-109. Review. PubMed PMID: 27713243; PubMed Central PMCID: PMC3991021. 17: Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003 Jul-Aug;49(4):422-5. PubMed PMID: 12918584. 18: Orsoni A, Thérond P, Tan R, Giral P, Robillard P, Kontush A, Meikle PJ, Chapman MJ. Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia. J Lipid Res. 2016 Nov;57(11):2073-2087. Epub 2016 Aug 31. PubMed PMID: 27581680; PubMed Central PMCID: PMC5087874. 19: Quinn C, Salameh JS, Smith T, Souayah N. Necrotizing myopathies: an update. J Clin Neuromuscul Dis. 2015 Mar;16(3):131-40. doi: 10.1097/CND.0000000000000065. Review. PubMed PMID: 25695918. 20: Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, Grabau D, Hedenfalk I, Borgquist S. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. J Transl Med. 2015 Apr 29;13:133. doi: 10.1186/s12967-015-0486-0. PubMed PMID: 25925673; PubMed Central PMCID: PMC4424530.

View History

Spirohydantoin-21

MedKoo CAT#: 464204

CAS#: unknown